LV009 / PersonGen Biomedicine - LARVOL DELTA

A novel CD7-VHH-retargeted lentiviral vector enables efficient, specific transduction of resting T/NK Cells for in vivo CAR-T/CAR-NK generation with potent anti-tumor efficacy and favorable safety (ASGCT 2026) - "(G) Serum levels of CAR-T function-related cytokines (Day 19 & 25). (H) H&E staining of major organs showed no pathological damage in the LV009 group."

CAR T-Cell Therapy • IO biomarker • Preclinical • Viral vector • Oncology • CD34 • CD7 • IL2RA

Clinical Study of LV009 Injection in the Treatment of Recurrent/Refractory CD19 Positive Blood Tumors (clinicaltrials.gov) - P1 | N=19 | Not yet recruiting | Sponsor: The First Affiliated Hospital with Nanjing Medical University

New P1 trial • Hematological Malignancies • Lymphoma • Oncology

Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malignancies (clinicaltrials.gov) - P1 | N=19 | Recruiting | Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd.

New P1 trial • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Clinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid Malignancies (clinicaltrials.gov) - P1 | N=10 | Recruiting | Sponsor: PersonGen BioTherapeutics (Suzhou) Co., Ltd.

New P1 trial • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malignancies (ChiCTR) - P=N/A | N=19 | Not yet recruiting | Sponsor: The First Affiliated Hospital of the University of Science and Technology of China; The First Affiliated Hospital of the University of Science and Tec

New trial • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology